I can see where the annual pivot would make it seem like management can't knuckle down where they want to go. I joined after FTO, so the PRV has never been on my radar.
I think considering PRV hasn't been at the forefront of a lot of presentations, I think those who believed in the company and PRV had the chance to exit at highs, as this has been like this for a while.
The company appears to align more like other RNA modifying companies where they have a lead asset and then are considering other molecules of note. It doesn't seem silly to make the drug more accessible for patients, as a CVL is much more cumbersome.
I like the direction(personally) management have taken, but I can see why some people who bought in last year may be disenchanted.
RAC - Charts & Price Action, page-10983
-
- There are more pages in this discussion • 10,612 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.89 |
Change
-0.050(2.58%) |
Mkt cap ! $313.4M | |||
| Open | High | Low | Value | Volume |
| $1.95 | $1.95 | $1.84 | $591.8K | 314.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11819 | $1.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 6846 | 1 |
View Market Depth
| Last trade - 14.37pm 15/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |